Contingencies and commitments
Contractual obligations and commitments
We entered into lease agreements for offices, laboratories and cars. As a consequence of the adoption of IFRS 16 Leases, on 1 January 2019, lease obligations in the scope of the new standard are presented as lease liabilities in the statements of financial position and no longer disclosed separately as off-balance sheet commitments.
We also have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.
On 30 June 2019 we had outstanding obligations for purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than 1 year |
1 - 3 years |
3 - 5 years |
More than 5 years |
Purchase commitments |
237,242 |
150,649 |
75,174 |
9,792 |
1,627 |
In addition to the table above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €48.4 million at 30 June 2019 for which we have direct purchase commitments of €19.1 million at 30 June 2019 reflected in the table above.
We refer to the section “Events after the end of the reporting period” of this interim report for the latest development in our collaboration with Gilead, which did not affect our financial statements for the first six months of 2019.
Contingent liabilities and assets
We refer to our annual report 2018 for a description of our contingent liabilities and assets as no material change is to be disclosed for the first six months of 2019.